Environmental Risk Assessment (ERA) / Environmental Assessment (EA) of GMOs

Broad Experience in Developing Effective Risk Management Strategies

Any activity involving Genetically Modified Organisms (GMOs) is subject to an Environmental Risk Assessment (ERA) / Environmental Assessment (EA) before initiation, depending on countries where approval is sought. Subsequently, an appropriate risk management strategy should be decided upon to mitigate potential adverse effects.

ProPharma Group provides a full range of services required to perform environmental studies, as well as offers consulting services, including ERA/EA, to the pharmaceutical and biotechnology industries. ProPharma Group’s expertise in both drug development and environmental testing enables us to set up these assessments completely, including relevant planned activities and risk management procedures for each GMO. Our experience allows us to determine the potential interaction between GMO(s) and the receiving environment to prevent environmental risk.